Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation

This publication has 32 references indexed in Scilit:

• Treatment of pancreatic cancer xenografts with Erbitux (IMC-C225) anti-EGFR antibody, gemcitabine, and radiation
  International Journal of Radiation Oncology*Biology*Physics, 2002
• The EGFR as a target for anticancer therapy—focus on cetuximab
  European Journal Of Cancer, 2001
• Phase I Study of Anti–Epidermal Growth Factor Receptor Antibody Cetuximab in Combination With Radiation Therapy in Patients With Advanced Head and Neck Cancer
  Journal of Clinical Oncology, 2001
• Clinical trial with escalating doses of the antiepidermal growth factor receptor humanized monoclonal antibody EMD 72 000 in patients with advanced squamous cell carcinoma of the larynx and hypopharynx
  Cancer Chemotherapy and Pharmacology, 2001
• Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy
  Critical Reviews in Oncology/Hematology, 2001
• Phase I Studies of Anti–Epidermal Growth Factor Receptor Chimeric Antibody C225 Alone and in Combination With Cisplatin
  Journal of Clinical Oncology, 2000
• Anti-(epidermal growth factor) receptor monoclonal antibodies for the induction of antibody-dependent cell-mediated cytotoxicity against squamous cell carcinoma lines of the head and neck
  Cancer Immunology, Immunotherapy, 1998
• Multiple infusions of anti-epidermal growth factor receptor (EGFR) monoclonal antibody (EMD 55 900) in patients with recurrent malignant gliomas
  European Journal Of Cancer, 1996
• Retinoic acid normalizes the increased gene transcription rate of TGF–α and EGFR in head and neck cancer cell lines
  Nature Medicine, 1996
• Pharmacokinetics of reshaped MAb 425 in three animal species
  Cell Biochemistry and Biophysics, 1995